Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other Accumulated Expenses (2016 - 2025)

Heron Therapeutics' Other Accumulated Expenses history spans 11 years, with the latest figure at $51.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 22.71% year-over-year to $51.2 million; the TTM value through Dec 2025 reached $51.2 million, up 22.71%, while the annual FY2025 figure was $51.2 million, 22.71% up from the prior year.
  • Other Accumulated Expenses reached $51.2 million in Q4 2025 per HRTX's latest filing, up from $48.5 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $52.4 million in Q2 2023 to a low of $24.7 million in Q1 2021.
  • Average Other Accumulated Expenses over 5 years is $39.2 million, with a median of $40.5 million recorded in 2023.
  • Peak YoY movement for Other Accumulated Expenses: dropped 23.68% in 2021, then soared 58.2% in 2023.
  • A 5-year view of Other Accumulated Expenses shows it stood at $25.9 million in 2021, then skyrocketed by 49.09% to $38.6 million in 2022, then increased by 8.57% to $41.9 million in 2023, then fell by 0.24% to $41.8 million in 2024, then rose by 22.71% to $51.2 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Other Accumulated Expenses are $51.2 million (Q4 2025), $48.5 million (Q3 2025), and $46.2 million (Q2 2025).